Evotec publishes company presentation outlining drug discovery strategy and value-creation levers

• Evotec outlined four mid-term value levers centered on above-market growth, operational excellence, improved monetization at Just Evotec Biologics, and higher returns from its asset pipeline.
• Operational plan targets FY 2025 cost-out of more than EUR 60 million, supported by about 600 FTE reductions in drug discovery and development from March 2024 to June 2025.
• Evotec flagged additional cost-reduction measures lifted to EUR 30 million impact in 2025, up from EUR 20 million.
• Just Evotec Biologics strategy emphasized shift toward higher-margin technology and IP revenue, supported by sale of its Toulouse J.POD site to Sandoz.
• Deal terms include about USD 350 million upfront payment in 2025, more than USD 300 million in license, milestone, and development revenues for 2026-2028, followed by royalties tied to 10 biosimilars from 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.